Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. Show more
Location: 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States | Website: https://www.geron.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
715M
52 Wk Range
$1.04 - $4.21
Previous Close
$1.10
Open
$1.08
Volume
7,307,677
Day Range
$1.08 - $1.13
Enterprise Value
459.5M
Cash
380.5M
Avg Qtr Burn
-33.23M
Insider Ownership
0.10%
Institutional Own.
80.93%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
RYTELO™ (Imetelstat) (GRN163L) Details Myelodysplastic syndrome | Approved Quarterly sales | |
Imetelstat (GRN163L) Details Myelofibrosis | Phase 3 Interim Update | |
Imetelstat (GRN163L) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 2 Data readout | |
Imetelstat (GRN163L)+ ruxolitinib Details Myelofibrosis | Phase 1b Data readout |
